JHVEPhoto My thesis After publishing a bullish thesis on Pfizer (NYSE:PFE) on June 5, the stock initially rallied, climbing to over $30 per share by the end of July. This surge seemed to validate the optimistic outlook. Pfizer's initial momentum, unfortunately, didn't last. The stock price dropped sharply following the Q2 earnings report release. This decline was particularly notable given the broader market context. While the overall stock market grew by 3% during this period, Pfizer's stock went again ...

The most recent trading session ended with Pfizer (PFE) standing at $28.39, reflecting a +0.32% shift from the previouse trading day's closing. This change outpaced the S&P 500's 0.16% loss on the day. Elsewhere, the Dow saw an upswing of 0.09%, while the tech-heavy Nasdaq depreciated by 0.3%.Heading into today, shares of the drugmaker had lost 3.48% over the past month, lagging the Medical sector's gain of 4.7% and the S&P 500's gain of 3.64% in that time.Investors will be eagerly watching for the performa ...

Pfizer Inc. (NYSE:PFE) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 8:30 AM ET Company Participants David Denton - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right, great. We're going to get started here. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Very pleased to be hosting Pfizer this morning, CFO, Dave Denton. I'm Terence Flynn from ...

Pfizer Inc. (NYSE:PFE) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 8:30 AM ET Company Participants David Denton - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right, great. We're going to get started here. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Very pleased to be hosting Pfizer this morning, CFO, Dave Denton. I'm Terence Flynn from ...

While market volatility may initially unsettle investors, it presents an opportunity to capitalize on discounted investment prospects. While the current bull market has favored some sectors, it hasn't been universally beneficial, leaving a trail of high-quality growth stocks facing significant price declines. Economic concerns, including a potential slowdown in the U.S. economy and the Bank of Japan's recent interest rate hike, have added fuel to this market turbulence. However, for those with a long-term i ...

Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseasesPfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs, ACE1831 in NHL and ACE2016 in solid tumorsAcepodia's lead ACC platform therapy has shown clinical benefits in oncology without the limitations of current CAR-T cell therapiesALAMEDA, Calif. and TAIPEI, Sept. 3, 2024 /PRNews ...

VLA15-221 Phase 2 study: strong immune response shown one month after a second booster dose (month 31) in pediatric and adult populationsSignificant anamnestic antibody response observed across all six serotypes, consistent with previous resultsFavorable safety profile of VLA15 observed in all age groups and for all vaccinations Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive immunogenicity and ...

A month has gone by since the last earnings report for Pfizer (PFE) . Shares have lost about 5.9% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Pfizer due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q2 Earnings & Sales BeatPfizer’s second-quarter results were ...

Pfizer (PFE) is launching a new direct-to-consumer (DTC) website called PfizerForAll, which will allow patients to order its marketed products for COVID-19, influenza and migraine directly.How the New PFE Platform WorksThe digital pharmacy will offer a convenient home delivery option for Pfizer medicines through third-party pharmacies. The new website also provides access to scheduling same-day appointments with independent healthcare professionals, either in-person or online.PFE is also offering adult user ...

Major drug companies are increasingly going direct-to-consumer.Shares of beleaguered drug store and pharmacy chain Walgreens Boots Alliance (WBA -8.81%) fell 8.4% on Tuesday as of 3:22 p.m. ET.The reason for the drop today appears to be twofold: One, Pfizer unveiled its own direct-to-consumer telehealth and e-commerce platform. Two, Eli Lilly announced it would be cutting prices for its GLP-1 drug Zepbound by 50% for certain doses, when ordered directly from the drugmaker's LillyDirect e-commerce platform.W ...